

**ENANTA Pharmaceuticals, Inc.**

500 Arsenal Street  
Watertown, Massachusetts  
02472

Tel: 617.607.0800  
Fax: 617.607.0530  
www.enanta.com

**For Immediate Release**

**CONTACT:**

Paul Kidwell  
617-296-3854  
[paul\\_kidwell@hotmail.com](mailto:paul_kidwell@hotmail.com)

*News Release*

**Enanta Pharmaceuticals Awarded Three US Patents for Novel  
Macrolide Antibiotics**



**WATERTOWN, Mass., October 9, 2002** – Enanta Pharmaceuticals, Inc. ([www.enanta.com](http://www.enanta.com)), a chemistry-driven biopharmaceutical company developing macrolide antibiotics and immunosuppressants, announced today that the United States Patent and Trademark Office has issued three U.S. Patents claiming novel classes of macrolide antibiotic compounds discovered by its scientists. The patents issued are: Number 6,436, 906, titled "9-Amino-14-Membered Macrolides Derived from Leucomycins," Number 6,440,942, titled "14-Membered Macrolides Derived from Leucomycins," and Number 6,462,026, titled "Bicyclic Leucomycins." The patents describe distinct classes of macrolide compounds that possess antibacterial activity toward Gram positive and Gram negative bacteria as well as macrolide resistant Gram positive pathogens. Enanta is actively engaged in macrolide antibiotic research and development.

"A significant part of Enanta's R&D effort is focused on developing new generation macrolide antibiotics for the treatment of respiratory tract infections," said Spiros Jamas, President and CEO of Enanta. "The issuance of three patents for novel macrolide compounds underscores Enanta's chemistry expertise and our goal of creating a broad intellectual property position."

The macrolide antibiotic family, comprising 14-, 15- and 16-membered ring compounds, exhibits a wide-ranging catalog of characteristics such as, antibacterial spectrum, side-effects and bioavailability. Enanta's patents relate to novel macrolide compounds, the processes for making them and methods for using them in the treatment of infections.

"These issued patents enhance Enanta's initiative in macrolide development allowing the Company to continue to impact a significant disease area," stated Dr. Yat Sun Or, Enanta's senior vice president, research and development. "We anticipate that our research in macrolides will lead to the development of new and improved therapeutics for diseases with unmet global medical needs."

- more -

**About Enanta**

Headquartered in Watertown, Mass., Enanta Pharmaceuticals is using its breakthrough chemistry technology -- *Drug Morphing*<sup>TM</sup> and *Peptide Morphing*<sup>®</sup> -- to create new intellectual properties by transforming existing drugs, natural products, and biologically active peptides into novel, small-molecule drugs. The Company is initially focusing on new chemical entities derived from existing drugs that address significant unmet medical needs: (a) new-generation macrolide antibiotics to overcome bacterial resistance; and (b) anti-inflammatory drugs for a variety of indications, including asthma, psoriasis and inflammatory bowel diseases.

###